Tirzepatide
Tirzepatide 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Obesity、Menopause Hot Flashes、Diabetes Mellitus, Type 1、Overweight。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
8 项
已进入 III/IV 期
19 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Mayo Clinic
- Eli Lilly and Company
- Regeneron Pharmaceuticals
- M.D. Anderson Cancer Center
- Arrowhead Pharmaceuticals
- Pennington Biomedical Research Center
- Ascletis Pharma (China) Co., Limited
- The University of Texas at Dallas
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、英国、澳大利亚、加拿大、瑞士、Moldova、Romania、Kuwait、比利时、Israel、意大利、Mexico
正在招募患者的 Tirzepatide 研究
GLP-1R Actions on Muscle and the Skeleton
IV 期招募中美国NCT07154719A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or Overweight
I 期招募中美国NCT07842640Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation
不适用招募中美国NCT073877962024 Tirzepatide-Bariatric Surgery
IV 期招募中美国NCT06721507Function and Lean Mass Preservation With Resistance Exercise During a GLP-1RA Treatment
不适用招募中英国NCT07457437Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease
II 期招募中美国NCT06976853Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity
II 期招募中美国NCT07228741Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes
II 期招募中澳大利亚NCT06820281Mechanisms of Weight Loss: Tirzepatide vs Semaglutide
IV 期招募中加拿大NCT07900074GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes
III 期招募中瑞士NCT06630585A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity
I 期 / II 期招募中美国MoldovaRomania英国NCT06842186A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar
II 期 / III 期招募中加拿大瑞士NCT07284511Tirzepatide Use in People With Obesity and Type 1 Diabetes
IV 期招募中KuwaitNCT07096908Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
III 期招募中美国比利时Israel意大利NCT07817875Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease
IV 期招募中美国NCT07058155Body Composition Changes After Initiation of GLP-1 Receptor Agonists in Adults With Obesity or Type 2 Diabetes
不适用招募中MexicoNCT07835360Tirzepatide Weight Loss for MRD+ Early Breast Cancer
II 期招募中美国NCT06517212Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity
I 期 / II 期招募中澳大利亚NCT07245771A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
II 期招募中美国NCT07527910Genetic, Microbiological and Behavioral Factors in Obesity
不适用招募中PolandNCT07650149GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity
不适用招募中中国NCT07633639A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
II 期招募中美国ArgentinaNCT06143956Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024
II 期招募中美国NCT07091734Effects of GLP-1 RAs on Human Lactation Outcomes
不适用招募中美国NCT07720414
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。